Where should analgesia lead to? Quality of life and functional recovery with tapentadol.
pain
quality of life
tapentadol
Journal
Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
10
2018
accepted:
27
02
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Chronic pain is a major health-care problem worldwide, affecting more than one out of five adults in Europe. Although multiple analgesic agents have been extensively investigated in terms of clinical response and tolerability profile, few studies have focused on the impact of these therapies on patients' quality of life (QoL). Of note, improvement in QoL, together with functional recovery, has been recognized since the late 1990s as two main goals of analgesic therapy. Tapentadol is a novel analgesic molecule that synergistically combines two mechanisms of action, µ-opioid receptor agonism and norepinephrine reuptake inhibition, and for which multiple literature data are available that confirm its efficacy and safety in controlling pain. This narrative review summarizes the information available on the impact of tapentadol on QoL, with the aim to provide clinicians with a comprehensive overview of the analgesic effects of tapentadol prolonged release beyond the reduction of pain.
Identifiants
pubmed: 31190967
doi: 10.2147/JPR.S190158
pii: 190158
pmc: PMC6529727
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1561-1567Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Eur J Pain. 2006 May;10(4):287-333
pubmed: 16095934
Curr Med Res Opin. 2005 Oct;21(10):1555-68
pubmed: 16238895
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006605
pubmed: 20091598
Adv Ther. 2010 Jun;27(6):381-99
pubmed: 20556560
Eur J Pain. 2010 Sep;14(8):781-3
pubmed: 20659810
Clin J Pain. 2012 Jan;28(1):8-13
pubmed: 21646907
Cochrane Database Syst Rev. 2011 Nov 09;(11):CD003113
pubmed: 22071805
Neurosci Lett. 2012 Jan 24;507(2):151-5
pubmed: 22197547
Curr Med Res Opin. 2012 Nov;28(11):1775-9
pubmed: 23057488
Curr Med Res Opin. 2014 Jun;30(6):1139-51
pubmed: 24528146
Pain Pract. 2016 Jun;16(5):600-19
pubmed: 26554630
Postgrad Med. 2016 Jun;128(5):502-15
pubmed: 27166559
J Opioid Manag. 2016 Sep/Oct;12(5):323-331
pubmed: 27844472
Br J Pain. 2016 Nov;10(4):217-221
pubmed: 27867511
Curr Med Res Opin. 2017 Aug;33(8):1413-1422
pubmed: 28537506
Expert Opin Drug Discov. 2018 Oct;13(10):965-972
pubmed: 30175624
Adv Ther. 2018 Oct;35(10):1471-1484
pubmed: 30206823
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365